Source Absorbable Enzymolysis Hemostatic Particles for Surgery

Strategic Sourcing Guide for Absorbable Enzymolysis Hemostatic Particles

Understanding the Product Category and Core Mechanisms

When sourcing absorbable enzymolysis hemostatic particles, buyers must first distinguish this category from traditional mechanical hemostats or chemical coagulants. The defining characteristic of these particles is their ability to stop bleeding through a combination of physical absorption and biological degradation. The core mechanism relies on a specific material composition, often derived from starch powders or potato powders, which creates a three-dimensional network structure upon application. This structure facilitates rapid clot formation, with observed performance metrics indicating blood clot strength can reach two to three times that of physiological blood clots.

The enzymolysis process is critical to the product's lifecycle within the human body. Unlike permanent implants, these agents are designed to degrade naturally. Data indicates a degradation timeline in the human body ranging from 14 days, while other observations suggest an enzymolysis window of 5 to 7 days depending on the specific formulation and application site. This rapid absorption is essential for preventing foreign body reactions and ensuring the surgical site heals without the need for secondary removal procedures. The application time is equally vital; effective products demonstrate the ability to achieve hemostasis within two to three minutes, significantly reducing operative time in general surgery scenarios.

Buyers should recognize that the raw material source is a primary differentiator. While some formulations utilize starch powder, others specify potato powder as the base, with compositions reaching 100% potato starch. This distinction impacts the enzymatic activity and the rate of degradation. The technology employed often involves reverse micro-emulsification, a process that ensures uniform particle size and consistent performance. Understanding these technical nuances is the first step in defining procurement requirements, as the mechanism of action directly influences the clinical outcomes and the regulatory pathway for the product.

Technical Specifications and Material Standards

Defining precise technical specifications is essential for ensuring that the purchased hemostatic particles meet the rigorous demands of surgical environments. The physical form of the product is typically a powder or sterile particles, packaged in blister cards or carton boxes. Standard specifications observed in the market include various gram weights, such as 0.5g, 1.0g, 2.0g, 3.0g, and 5.0g. These variations allow surgeons to select the appropriate dosage based on the size of the wound or the extent of bleeding. The packaging often includes a gift box configuration for retail or specific hospital procurement channels, though the primary functional unit is the sterile blister pack.

The storage and stability requirements are equally critical for maintaining product efficacy. Buyers must verify that the supply chain can maintain specific environmental conditions. Recommended storage parameters indicate a relative humidity of no more than 85%, and temperature constraints often specify avoiding storage below -40 ℃ or above 60 ℃. These limits ensure that the three-dimensional network structure remains intact and that the enzymatic properties are preserved until the moment of use. The shelf life for these products is typically three years, which aligns with the quality guarantee period often offered by manufacturers.

It is important to note that while some products feature ethylene oxide sterilization, others may be processed without it, or the data may present conflicting observations regarding this specific method. Buyers must explicitly confirm the sterilization status of the specific lot they intend to purchase, as this impacts the regulatory classification and the safety profile of the device. The product is classified as a Class III instrument in some jurisdictions, which necessitates a higher level of scrutiny regarding the manufacturing process and quality control measures.

Compliance, Certification, and Regulatory Alignment

Navigating the regulatory landscape for absorbable hemostatic particles requires a thorough understanding of international certifications and local compliance standards. The most frequently observed certifications for these products include CE marking and ISO standards. These certifications are critical indicators that the manufacturer adheres to specific quality management systems and safety requirements. Some listings also reference ISOCE, which may imply a combined compliance status, but buyers should verify the specific ISO standard (e.g., ISO 13485 for medical devices) to ensure it covers the entire lifecycle of the product.

The regulatory classification of the product is a significant factor in the procurement process. With an instrument classification of Class III, these devices are considered high-risk, requiring rigorous pre-market approval in many regions. This classification underscores the importance of verifying that the supplier has the necessary regulatory approvals for the target market. The indications for use are generally listed as absorbable hemostatic agents for stopping bleeding in surgery, specifically for general surgery applications. However, buyers must ensure that the specific product model, such as "Surgiclean" or "Quickclean Absorbable Hemostatic Particles," is approved for the specific surgical procedures they intend to perform.

Compliance also extends to the labeling and packaging standards. Products often carry the "Jonor" designation, referring to high-quality manufactured products from Zhejiang, China, but this is a regional identifier rather than a universal standard. Buyers should look for explicit statements regarding the product standard, which may vary by model. The presence of a logo printing option suggests that customization is available, but this must be done in compliance with regulatory labeling requirements. Any custom branding must not obscure critical information such as the batch number, expiration date, or sterilization method.

Cost Drivers and Supply Chain Economics

The pricing structure for absorbable enzymolysis hemostatic particles is influenced by several factors, including the complexity of the manufacturing process, the raw material quality, and the level of customization required. The observed price range in the market spans from 1.2 USD to 78 USD, reflecting a wide variance based on product specifications, packaging, and order volume. This broad range indicates that buyers should not assume a single price point but rather evaluate the cost in the context of the specific technical requirements and volume needs.

The minimum order quantity (MOQ) is another significant cost driver, with observed ranges extending from 1 unit to 10,000 units. For hospitals or distributors seeking to test the product or fulfill small-scale needs, lower MOQs are available. However, for large-scale procurement, negotiating a lower unit price typically requires meeting higher volume thresholds. The supply type offered by manufacturers often includes OEM (Original Equipment Manufacturer), OBL (Original Brand License), and distribution channels. This flexibility allows buyers to source products under their own brand or as a distributor of established brands, each with different cost implications.

Customization is a key feature that impacts cost. Options such as logo printing and customized packaging add value but may increase the unit price or require a higher MOQ. The location of the manufacturer, often cited as Hangzhou, China, influences logistics costs and lead times. While the origin is a known variable, the actual lead time can vary based on the supplier's current production capacity and the specific order size. Buyers should factor in these logistical variables when calculating the total cost of ownership, rather than focusing solely on the unit price.

Supplier Evaluation and Manufacturing Capabilities

Evaluating suppliers for absorbable hemostatic particles requires a deep dive into their manufacturing capabilities and business model. The majority of suppliers in this category identify as manufacturers rather than simple distributors, which suggests a direct control over the production process. This is a critical advantage for ensuring quality consistency and traceability. The supply type often listed as "OEM, Obl, Distribute" indicates that these manufacturers are capable of producing products for various clients, including private label opportunities.

When assessing a potential supplier, buyers should verify the "Company" attribute to ensure they are dealing with a legitimate manufacturing entity. The presence of a "Company" designation as "Manufacture" implies that the supplier has the infrastructure to handle the reverse micro-emulsification technology and the specific raw material processing required. Buyers should also check for the availability of customization services, as the ability to tailor the product to specific clinical needs can be a decisive factor in supplier selection.

The geographic origin of the products, frequently listed as Hangzhou, China, or generally China, provides context for the supply chain. While this location is a hub for medical device manufacturing, buyers should verify the specific factory location and audit the facility if possible. The "Jonor" attribute, referring to Zhejiang High-Quality Manufactured Products, serves as a regional quality indicator but should not be the sole basis for supplier selection. Instead, buyers should rely on the supplier's track record, certification status, and ability to meet the specific technical and regulatory requirements of their market.

Quality Control and Long-Term Procurement Strategy

Maintaining high quality standards is paramount when sourcing Class III medical devices like absorbable hemostatic particles. Quality control measures must be robust, covering the entire production process from raw material sourcing to final packaging. The use of 100% potato starch or starch powder must be verified through incoming material inspections. The sterilization process, whether ethylene oxide or otherwise, must be validated to ensure the product is free from contaminants and safe for surgical use. The quality guarantee period, often cited as two to three years, serves as a benchmark for the expected shelf life, but buyers should always check the specific expiration dates on the product packaging.

Long-term procurement strategies should focus on building relationships with suppliers who demonstrate a commitment to continuous improvement and regulatory compliance. The ability to provide consistent product specifications, such as the three-dimensional network structure and the specific degradation times, is essential for maintaining clinical efficacy. Buyers should also consider the availability of after-sales support and the supplier's ability to handle recalls or quality issues promptly. The "Disposable" nature of the product means that waste management and environmental impact may also be considerations for long-term sustainability strategies.

In conclusion, sourcing absorbable enzymolysis hemostatic particles requires a comprehensive approach that balances technical specifications, regulatory compliance, cost considerations, and supplier reliability. By focusing on the core mechanisms of enzymolysis, verifying the raw material composition, and ensuring adherence to international certifications, buyers can secure high-quality products that meet the demanding needs of modern surgical practices. The wide range of available options, from different gram weights to customization features, allows for tailored procurement strategies that align with specific clinical and operational requirements.